Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18515
Country/Region: Kenya
Year: 2017
Main Partner: Eastern Deanery AIDS Relief Program
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: HHS/CDC
Total Funding: $6,389,279 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $311,804
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $1,179,684
Testing: HIV Testing and Counseling (HVCT) $995,209
Sexual Prevention: Other Sexual Prevention (HVOP) $91,323
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $272,899
Treatment: Adult Treatment (HTXS) $3,356,479
Treatment: Pediatric Treatment (PDTX) $181,881
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2018 1,405
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2018 498
GEND_GBV <10, Male, Physical and/or Emotional Violence 2018 275
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2018 111
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 841
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 250
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 88
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 82
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 786
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 164
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 80
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2018 7
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 1,740
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 311
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 110
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 13
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 786
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 1,233
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 68
GEND_GBV 25-49, Male, Sexual Violence (Post-Rape Care) 2018 63
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2018 56
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2018 26
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2018 3
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 1,105
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 6,244
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 2,762
GEND_GBV Number of people receiving post-GBV care 2018 9,006
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 205,027
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2018 1,834
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2018 3,984
HTS_TST Service Delivery Point (Facility) ANC: 25-49, Negative 2018 4,731
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2018 107
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2018 3,391
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2018 649
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2018 631
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 462
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 229
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 264
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 131
HTS_TST Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 678
HTS_TST Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 705
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2018 87
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2018 91
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 2,399
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 1,046
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 579
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 1,572
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 966
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 3,487
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 1,336
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 7,478
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 3,306
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 721
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 397
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2018 6,823
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2018 47
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2018 41
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 19
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2018 17
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 65
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 93
HTS_TST Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 166
HTS_TST Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 469
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2018 34
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 5,516
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 2,106
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 3,051
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 8,367
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 4,567
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 17,917
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 9,233
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 40,228
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 31,026
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2018 2,439
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2018 3,015
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2018 8,738
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2018 2,186
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2018 2,186
HTS_TST Service Delivery Point (Facility) VMMC: 25-49, Negative 2018 8,520
HTS_TST Service Delivery Point (Facility) VMMC: 50+, Negative 2018 216
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2018 86
HTS_TST Sum of Test Result disaggregates 2018 6,595
HTS_TST_POS By Test Result: Positive 2018 6,595
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2018 114
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2018 423
HTS_TST_POS Service Delivery Point (Facility) ANC: 25-49, Positive 2018 1,319
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 16
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 79
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 69
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2018 14
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 12
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 45
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 15
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 243
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 217
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 32
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 25
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2018 13
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2018 13
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2018 24
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2018 57
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 204
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 229
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2018 16
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2018 30
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2018 39
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2018 53
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2018 12
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2018 13
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2018 56
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2018 29
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2018 243
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 87
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 1,312
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 1,171
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2018 176
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2018 125
PMTCT_ART Already on ART at beginning of current pregnancy 2018 978
PMTCT_ART New on ART 2018 785
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 1,763
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 12,405
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 1,763
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 321
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 1,394
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 29
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 19
PMTCT_STAT By Age (Numerator): 15-19 2018 1,948
PMTCT_STAT By Age (Numerator): 20-24 2018 4,407
PMTCT_STAT By Age (Numerator): 25-49 2018 6,050
PMTCT_STAT By Number of known positives: 15-19 2018 28
PMTCT_STAT By Number of known positives: 20-24 2018 146
PMTCT_STAT By Number of known positives: 25-49 2018 804
PMTCT_STAT By Number of new negative: 15-19 2018 1,834
PMTCT_STAT By Number of new negative: 20-24 2018 3,984
PMTCT_STAT By Number of new negative: 25-49 2018 4,731
PMTCT_STAT By Number of new positives: 15-19 2018 86
PMTCT_STAT By Number of new positives: 20-24 2018 277
PMTCT_STAT By Number of new positives: 25-49 2018 515
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 12,405
PMTCT_STAT_den By Age (Denominator): <15-19 2018 1,948
PMTCT_STAT_den By Age (Denominator): 20-24 2018 4,407
PMTCT_STAT_den By Age (Denominator): 25-49 2018 6,050
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 13
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 299
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 13
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 273
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 598
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 598
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 13
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 299
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 13
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 273
TB_PREV By Age/Sex (Numerator): <15, Female 2018 75
TB_PREV By Age/Sex (Numerator): <15, Male 2018 72
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 3,952
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 1,837
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 5,936
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 6,595
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 86
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 82
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 4,388
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 2,039
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 60
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 550
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 54
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 887
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 1,551
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 1,556
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 81
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 543
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 59
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 873
TX_CURR Age/Sex: <1 2018 48
TX_CURR Age/Sex: <1-9 2018 734
TX_CURR Age/Sex: 10-14 Female 2018 368
TX_CURR Age/Sex: 10-14 Male 2018 347
TX_CURR Age/Sex: 15-19 Female 2018 298
TX_CURR Age/Sex: 15-19 Male 2018 214
TX_CURR Age/Sex: 20-24 Female 2018 1,031
TX_CURR Age/Sex: 20-24 Male 2018 198
TX_CURR Age/Sex: 25-49 Female 2018 15,144
TX_CURR Age/Sex: 25-49 Male 2018 6,842
TX_CURR Age/Sex: 50+ Female 2018 2,362
TX_CURR Age/Sex: 50+ Male 2018 1,911
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 29,497
TX_CURR Sum of age/sex disaggregates 2018 512
TX_NEW Breastfeeding status 2018 79
TX_NEW By Age/Sex: <1 2018 48
TX_NEW By Age/Sex: 1-9 2018 67
TX_NEW By Age/Sex: 10-14 Female 2018 26
TX_NEW By Age/Sex: 10-14 Male 2018 27
TX_NEW By Age/Sex: 15-19 Female 2018 209
TX_NEW By Age/Sex: 15-19 Male 2018 47
TX_NEW By Age/Sex: 20-24 Female 2018 784
TX_NEW By Age/Sex: 20-24 Male 2018 115
TX_NEW By Age/Sex: 25-49 Female 2018 3,157
TX_NEW By Age/Sex: 25-49 Male 2018 1,686
TX_NEW By Age/Sex: 50+ Female 2018 238
TX_NEW By Age/Sex: 50+ Male 2018 191
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 6,595
TX_NEW Pregnancy status 2018 707
TX_NEW Sum of Age/Sex disaggregates 2018 6,480
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 29,450
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 26,360
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 545
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 41
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 534
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 40
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 15,766
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 1,184
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 7,670
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 580
TX_PVLS Numerator: Indication: Routine 2018 24,515
TX_PVLS Numerator: Indication: Targeted 2018 1,845
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Routine 2018 130
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Targeted 2018 10
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 861
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Targeted 2018 68
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 681
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 50
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 668
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 51
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 17,518
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 1,317
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 8,522
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 643
TX_PVLS_den Denominator: Indication: Routine 2018 27,389
TX_PVLS_den Denominator: Indication: Targeted 2018 2,061
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Routine 2018 142
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Targeted 2018 10
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 955
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Targeted 2018 73
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 81
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 78
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 4,169
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,937
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 6,265
TX_RET Numerator by Status: Breastfeeding 2018 75
TX_RET Numerator by Status: Pregnant 2018 672
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 6,595
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 86
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 82
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 4,388
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 2,039
TX_RET_den Denominator by Status: Breastfeeding 2018 79
TX_RET_den Denominator by Status: Pregnant 2018 707
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 29,497
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 239
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 10
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 10
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 86
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 133
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 755
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 742
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 18,835
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 9,165
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 4,720
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 294
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 886
TX_TB_den Denominator: By Screen Result: Negative 2018 23,597
TX_TB_den Denominator: By Screen Result: Positive 2018 5,900
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 5,900
VMMC_CIRC By Age: 10-14 2018 9,833
VMMC_CIRC By Age: 15-19 2018 2,348
VMMC_CIRC By Age: 20-24 2018 2,191
VMMC_CIRC By Age: 25-29 2018 4,371
VMMC_CIRC By Age: 30-49 2018 4,160
VMMC_CIRC By Age: 50+ 2018 216
VMMC_CIRC By circumcision technique: Device-based VMMC 2018 1,406
VMMC_CIRC By circumcision technique: Surgical VMMC 2018 21,713
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2018 23,119
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2018 23,119
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2018 14,588
Cross Cutting Budget Categories and Known Amounts Total: $3,501,296
Gender: Gender Based Violence (GBV) $89,149
Post GBV Care
Implementation
Capacity building
GBV Prevention
Implementation
Capacity building
Key Populations: MSM and TG $33,627
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: Sex Workers $78,520
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Human Resources for Health $3,300,000